The authors summarize currently approved tyrosine kinase inhibitors for HER2+ breast cancer, key clinical trials, and their use in current clinical practice.
[npj Breast Cancer]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Mammary Cell News HER2-Positive Breast Cancer and Tyrosine Kinase Inhibitors: The Time Is Now
